{
    "url_original": "https://www.wsj.com/articles/wsj-wealth-adviser-briefing-big-pharma-checkup-reviving-zombie-brands-high-end-purchasing-01608202933?mod=markets_major_pos7",
    "url": "wsj-wealth-adviser-briefing-big-pharma-checkup-reviving-zombie-brands-high-end-purchasing-01608202933",
    "title": "WSJ Wealth Adviser Briefing: Big Pharma Checkup, Reviving Zombie Brands, High-End Purchasing",
    "sub_head": "Curated news and analysis for wealth advisers and their clients from WSJ reporters and columnists",
    "category_1": "Moneybeat Blog",
    "time": "2020-12-17 06:02:00",
    "body": "The bond market has a message for every issuer: Borrow! More! Money!<br />Yields are close to as low as they have ever been. Should you be loading up on debt to pour into stocks, property and other things that might produce a return above the cost of repaying the loan? One notable investor shows how getting everything right can deliver fat returnsâ€”but still come with a hefty drawback.<br />Below, some of the best analysis and insight from WSJ writers and columnists, the Dow Jones Newswires team and occasionally beyond, on investing, the wealth-management business and more.<br />CORONAVIRUS OUTLOOK<br />New Business Owners Look Beyond Covid-19, and Winter: Entrepreneurs seize deals, see opportunity in crisis."
}